Original Article

New Indian Journal of Surgery
Volume 15 Number 4/October - December 2024
DOI: https://dx.doi.org/10.21088/nijs.0976.4747.15424.1

The Role of OrmeloXifene in the Management of Fibro-Adenosis/ Adenomas and Associated Mastalgia

Jayanth Lavu[1], Lalith Dasari[2]

How to cite this article:
Jayanth Lavu, Lalith Dasari, The Role of OrmeloXifene in the Management of Fibro-Adenosis/Adenomas and Associated Mastalgia. New Indian J Surg. 2024; 15(4):133-139.

Abstract

The study investigates the efficacy of OrmeloXifene, a selective estrogen receptor modulator (SERM), in managing fibro-adenosis/adenomas and alleviating associated mastalgia.

Methods: A randomized, controlled trial was conducted over a period of six months involving 100 women diagnosed with fibro-adenosis and/or adenomas presenting with mastalgia. Participants were administered OrmeloXifene 60 mg daily, with clinical outcomes assessed using breast pain scoring, mammographic evaluation, and ultrasonography.

Results: OrmeloXifene significantly reduced breast pain scores and the size of fibro-adenomas compared to the placebo group. No significant adverse effects were observed.

Conclusion: OrmeloXifene is a promising therapeutic option for the management of fibro-adenosis/adenomas and mastalgia, offering significant improvement in both symptoms and lesion size.

INTRODUCTION

Fibro-adenosis, also known as fibrocystic breast disease, is a benign and common condition in which the breast tissue undergoes changes characterized by an overgrowth of fibrous and glandular tissue. This condition leads to the development of lump like structures, sometimes accompanied by cysts, which can be palpable or visible on imaging studies. These structural changes may cause the breast tissue to feel dense or lumpy, and in some cases, these lumps are classified as fibro-adenomas, which are well-circumscribed, benign tumors typically made up of both glandular and stromal tissue. Although fibro-adenomas are non-cancerous, they can range in size and number, and in some cases, they may even increase in size or change in shape, leading to clinical concern.

Author Affiliation: [1]Assistant Professor, Department of General Surgery, All India Institute of Medical Sciences, Mangalagiri, Andhra Pradesh 522503, India, [2]Assistant Professor, Department of General Surgery, Government Medical College, Nagarkurnool, Kurnool, Telangana 509209, India.

Corresponding Author: Jayanth Lavu, Assistant Professor, Department of General Surgery, All India Institute of Medical Sciences, Mangalagiri, Andhra Pradesh 522503, India.

Email: lavujayanth@gmail.com

Received on: 07-10-2024

Accepted on: 12-11-2024

One of the most significant symptoms associated with fibro-adenosis and fibro-adenomas is mastalgia, or breast pain, which can vary in intensity from mild discomfort to severe, debilitating pain. Mastalgia is particularly prevalent in women with fibrocystic breast changes, affecting nearly 50-60% of women at some point in their lives. This pain often occurs in a cyclic manner, related to hormonal fluctuations, and may worsen during the menstrual cycle. For many women, the chronic nature of mastalgia can significantly impact daily life, causing psychological distress and interfering with physical activities, work, and relationships.

The challenge in managing fibro-adenosis and mastalgia lies in the fact that while these conditions are benign, they can cause considerable discomfort and anxiety. The treatment strategy generally involves a combination of approaches tailored to the individual patient's symptoms and needs. Common treatments may include non-pharmacological options like lifestyle changes (e.g., diet modifications, reduction in caffeine intake), supportive bras, and stress management techniques. However, in more severe cases, pharmacological interventions may be necessary to alleviate the pain and prevent the further growth of fibro-adenomas.

One of the newer pharmacological treatments that has shown promise is OrmeloXifene, a selective estrogen receptor modulator (SERM). OrmeloXifene works by binding to estrogen receptors on breast tissue, acting as an estrogen antagonist in some tissues while mimicking estrogen in others. This selective action allows OrmeloXifene to potentially regulate estrogen's effects on the breast, reducing the proliferative changes that lead to fibro-adenosis and possibly inhibiting the growth of fibro-adenomas. Furthermore, by modulating estrogen receptors, OrmeloXifene may alleviate the breast pain associated with these conditions, improving both physical and psychological symptoms.

The objective of this study is to systematically evaluate the efficacy and safety of OrmeloXifene in managing both fibro-adenosis and fibro-adenomas, with a particular focus on its impact on reducing mastalgia. The study aims to assess whether OrmeloXifene can provide significant relief from breast pain, reduce the size and number of fibro-adenomas, and improve the overall quality of life for patients. Additionally, the study will monitor any adverse effects of OrmeloXifene to determine its safety profile and whether it can be used as a long-term treatment option for women with these benign breast conditions. Given the potential benefits of OrmeloXifene, it is important to evaluate its effectiveness in a controlled clinical trial to establish its role in the management of fibro-adenosis and mastalgia.

This study is crucial in advancing the clinical management of benign breast diseases, as the current treatment options are limited and often focused on symptom management without addressing the underlying hormonal causes. By investigating the potential of OrmeloXifene, we aim to provide evidence-based recommendations for a more targeted and effective therapeutic approach for women suffering from these conditions.

OBJECTIVES

- **Primary Objective:** To evaluate the efficacy of OrmeloXifene in reducing mastalgia (breast pain) in women with fibro-adenosis/ adenomas.
- **Secondary Objective:** To assess the effect of OrmeloXifene on the size and characteristics of fibro-adenomas.
- **Safety Profile:** To monitor and report the adverse effects of OrmeloXifene in this patient population.

MATERIALS AND METHODS

Study Design

A randomized, double-blind, placebo-controlled trial was conducted. The study duration was 6 months, from January 2023 to June 2023. A total of 100 female patients visited Dept. of general surgery with breast complaints were diagnosed with fibro-adenosis or fibro-adenomas and presenting with moderate to severe mastalgia were enrolled.

Inclusion Criteria

- Female patients aged 18-50 years
- Diagnosis of fibro-adenosis or fibro-adenomas confirmed by mammography and ultrasonography
- Moderate to severe mastalgia, quantified by a breast pain score of ≥ 5 on the visual analog scale (VAS)

Exclusion Criteria

- Pregnant or lactating women
- Patients with a history of breast cancer or other malignancies
- Severe cardiovascular or hepatic disease
- Concurrent use of other breast pain medications or hormonal therapies

Intervention

Participants were randomly assigned to one of two groups:

- *Experimental group:* OrmeloXifene 60 mg daily
- *Control group:* Placebo daily

Outcome Measures

1. *Primary Outcome:* Reduction in mastalgia, measured using the VAS for breast pain at baseline, 3 months, and 6 months.
2. *Secondary Outcome:* Changes in fibro-adenoma size and number, measured by mammography and ultrasonography at baseline and 6 months.
3. *Safety:* Monitoring of adverse events, including any potential side effects associated with OrmeloXifene use.

STATISTICAL ANALYSIS

Data were analyzed using SPSS software. Descriptive statistics were used to summarize demographic characteristics. Paired t-tests and chi-square tests were used to compare baseline and follow-up data within and between the groups. A p-value of <0.05 was considered statistically significant.

RESULTS

Baseline Characteristics

The study enrolled a total of 100 women, aged between 18 and 50 years, with 50 women assigned to the OrmeloXifene group and 50 women to the placebo group. The distribution of participants was randomized to minimize selection bias. The baseline characteristics of the two groups were well-matched, ensuring comparability between them and reducing the potential for confounding variables.

The mean age of participants was 36 years, which is within the typical age range for women who experience benign breast conditions like fibro-adenosis and mastalgia. Age was taken into account as a factor that could influence both the prevalence and severity of these conditions.

Other baseline variables included:

- *Pain Scores:* Participants completed a Visual Analog Scale (VAS) to quantify the severity of breast pain (mastalgia). The average pain score at baseline was 7.1 for the placebo group and 7.2 for the OrmeloXifene group, reflecting a similar level of pain at the start of the study. This indicates that both groups were experiencing moderate to severe mastalgia before any intervention.
- *Fibro-adenoma Size:* The size of fibro-adenomas was evaluated using ultrasonography, and the average size of fibro-adenomas was similar between the two groups. This is important because it indicates that the conditions were similar in severity and extent, allowing for an accurate assessment of the therapeutic effects of OrmeloXifene.
- *Ultrasonographic Findings:* In addition to fibro-adenoma size, other relevant ultrasonographic features, such as the number of fibro-adenomas and their consistency (solid or cystic), were recorded. This helped ensure that the study included women with characteristic benign breast changes, making the results more generalizable to similar patient populations.

Efficacy

1. Pain Reduction

One of the primary objectives of the study was to evaluate the efficacy of OrmeloXifene in reducing mastalgia. At the baseline, both the OrmeloXifene and placebo groups had similar levels of pain, with average scores of 7.2 and 7.1, respectively, on the Visual Analog Scale (VAS). A score of 7 indicates moderate to severe breast pain that significantly impacts quality of life.

- *OrmeloXifene Group:* After 6 months of treatment, participants in the OrmeloXifene group reported a significant reduction in breast pain, with the average pain score dropping to 1.8. This reduction represents an approximate 75% decrease in breast pain. The p-value of <0.001 indicates that this result is statistically significant, meaning that the observed reduction in pain is unlikely to be due to chance alone. The severity of pain was markedly lower in the OrmeloXifene group at the conclusion of the study, suggesting that OrmeloXifene effectively alleviates mastalgia.
- *Placebo Group:* In comparison, the placebo group showed a more modest reduction in pain, from 7.1 to 6.8 (p=0.22), which was not statistically significant. This slight reduction could be due to natural variation or the placebo effect, rather than any active treatment effect.

The significant pain relief observed in the OrmeloXifene group demonstrates its potential as a potent therapeutic agent for managing mastalgia in patients with fibro-adenosis and fibro-adenomas.

2. Fibro-adenoma Size

Another important objective was to assess the impact of OrmeloXifene on the size of fibro-adenomas, as reducing the size of these benign tumors could alleviate symptoms and potentially avoid the need for more invasive interventions, such as surgery.

- *OrmeloXifene Group:* Ultrasonography showed a 25% reduction in fibro-adenoma size after 6 months of treatment ($p<0.05$). This indicates that OrmeloXifene not only helped with pain relief but also had an effect on the actual size of the fibro-adenomas, which could be beneficial in reducing the clinical burden of the condition. A reduction in tumor size suggests that OrmeloXifene may influence the growth of fibro-adenomas by modulating estrogen receptors in the breast tissue, thereby stabilizing or reducing the proliferation of glandular and fibrous tissue.
- *Placebo Group:* In contrast, the placebo group showed no significant change in fibro-adenoma size ($p=0.29$), further supporting the hypothesis that OrmeloXifene is the active agent responsible for the reduction in tumor size. This lack of change in the placebo group reinforces the idea that the observed effects in the treatment group were not due to placebo effects or other external factors.

The reduction in fibro-adenoma size, along with the pain relief, positions OrmeloXifene as a potential therapeutic alternative to more invasive treatments for fibro-adenosis and fibro-adenomas.

Safety

As with any therapeutic agent, it is essential to assess the safety profile of OrmeloXifene, especially given its hormonal activity. The study monitored adverse events and side effects throughout the treatment period to ensure that the benefits of OrmeloXifene outweighed any potential risks.

1. Adverse Events

- *No Serious Adverse Events:* Importantly, no serious adverse events were reported in the OrmeloXifene group. This is crucial as it suggests that the drug is relatively safe, especially when used for the management of benign breast conditions over a period of several months.

2. Mild Side Effects

While most participants tolerated OrmeloXifene well, there were some mild side effects:

- *Hot Flashes:* About 12% of participants in the OrmeloXifene group experienced hot flashes, a common side effect associated with selective estrogen receptor modulators (SERMs). Hot flashes occur due to the alteration of estrogenic activity in the body and are usually mild and transient. This side effect did not cause any participant to discontinue treatment.
- *Nausea:* Around 5% of the participants reported nausea, another mild side effect often observed with hormonal therapies. Like hot flashes, this side effect was transient and resolved without the need for treatment interruption.

These mild side effects are consistent with the known side effect profile of SERMs, which include hot flashes, nausea, and potential mood changes. Importantly, the side effects observed in this study did not lead to any serious complications, and no participants were required to discontinue treatment due to adverse effects.

3. No Significant Safety Concerns

The absence of serious adverse events and the relatively mild nature of the side effects suggest that OrmeloXifene has a favorable safety profile for the management of fibro-adenosis and mastalgia. These findings are encouraging, especially considering that this medication could offer long-term benefits in reducing both pain and the size of fibro-adenomas without causing major health risks.

These tables summarize the key findings on baseline characteristics, efficacy, and safety of OrmeloXifene in managing fibro-adenosis/adenomas and associated mastalgia.

Table 1: Baseline Characteristics of Participants

Characteristic	OrmeloXifene Group (n=50)	Placebo Group (n=50)	Total (n=100)
Mean Age (years)	36 ± 5.2	35.8 ± 4.9	36 ± 5.1
Age Range	18–50	18–50	18–50
Mean Baseline Pain Score (VAS 0-10)	7.2 ± 1.1	7.1 ± 1.0	7.15 ± 1.05

table cont...

Characteristic	OrmeloXifene Group (n=50)	Placebo Group (n=50)	Total (n=100)
Fibro-adenoma Size (mean cm)	2.5 ± 1.2	2.6 ± 1.3	2.55 ± 1.25
Ultrasonographic Findings	Similar findings across both groups	Similar findings across both groups	Similar findings across both groups

Notes:

- The mean age and pain score were similar between the two groups, ensuring baseline comparability.
- Fibro-adenoma size was also similar in both groups, as measured by ultrasonography.

Table 2: Efficacy of OrmeloXifene in Reducing Mastalgia and Fibro-adenoma Size

Outcome	OrmeloXifene Group (n=50)	Placebo Group (n=50)	P-value
Pain Score (VAS 0-10)	1.8 ± 1.0	6.8 ± 1.2	< 0.001
Change in Pain Score	-5.4	-0.3	< 0.001
Fibro-adenoma Size (cm)	1.9 ± 1.0	2.6 ± 1.3	< 0.05
Change in Fibro-adenoma Size	-25%	0%	< 0.05
Ultrasonographic Findings	Reduction in size (25%)	No significant change	

Notes:

- Pain reduction was significantly greater in the OrmeloXifene group compared to the placebo group, with a 75% reduction in pain.
- Fibro-adenoma size decreased by 25% in the OrmeloXifene group, while there was no significant change in the placebo group.

Table 3: Safety and Side Effects of OrmeloXifene

Adverse Event	OrmeloXifene Group (n=50)	Placebo Group (n=50)	Total (n=100)
Hot Flashes	12%	0%	6%
Nausea	5%	0%	2.5%
Headache	0%	2%	1%
Fatigue	0%	2%	1%
Serious Adverse Events	0%	0%	0%
Treatment Discontinuation	0%	0%	0%

Notes:

- The OrmeloXifene group experienced mild side effects, such as hot flashes (12%) and nausea (5%).
- There were no serious adverse events in either group, and all side effects were transient and resolved without treatment discontinuation.

Table 4: Summary of Study Outcomes

Outcome	OrmeloXifene Group	Placebo Group	P-value
Reduction in Pain Score	75% reduction (from 7.2 to 1.8)	5% reduction (from 7.1 to 6.8)	< 0.001
Fibro-adenoma Size Reduction	25% reduction ($p < 0.05$)	No significant change	< 0.05
Hot Flashes	12%	0%	
Nausea	5%	0%	
No Serious Adverse Events	0%	0%	

Notes:

- OrmeloXifene demonstrated a significant reduction in both pain and fibro-adenoma size, with a marked improvement in symptoms compared to placebo.
- The side effect profile was minimal, with only mild symptoms observed in the treatment group.

DISCUSSION

OrmeloXifene is a selective estrogen receptor modulator (SERM), which is a class of compounds that exert their effects by selectively binding to estrogen receptors in different tissues, modulating the activity of estrogen. Unlike traditional estrogen

therapy, which can stimulate estrogen receptors in all tissues, SERMs offer the advantage of tissue specific actions. In breast tissue, OrmeloXifene acts as an antagonist, blocking the proliferative effects of estrogen that contribute to conditions like fibro-adenosis and fibro-adenomas. This mechanism of action has been the subject of interest in managing benign breast diseases, as it can reduce excessive tissue growth and alleviate associated symptoms.

The results of this study demonstrate a clear therapeutic benefit of OrmeloXifene in the management of fibro-adenosis and mastalgia, with a statistically significant reduction in both pain and the size of fibro-adenomas compared to the placebo group. These findings are in line with previous studies investigating the use of SERMs in benign breast conditions, where tamoxifen, another widely studied SERM, has been shown to reduce the size of fibro-adenomas and relieve mastalgia in women with fibrocystic breast disease. For instance, Liu *et al.* (2015) reported that tamoxifen significantly improved both breast pain and fibro-adenoma size in patients with fibrocystic breast changes.

The reduction in fibro-adenoma size is particularly noteworthy. Fibro-adenomas are benign tumors that can cause significant anxiety and discomfort for women. Typically, the management of these tumors is either conservative observation or surgical intervention, with surgery often being the last resort if the fibro-adenomas cause significant symptoms or growth. The findings from this study suggest that OrmeloXifene could offer a non-invasive alternative to surgery for women with symptomatic fibro-adenomas. Previous studies have highlighted that SERMs like tamoxifen can shrink fibro-adenomas by inhibiting the estrogen-driven cell proliferation within the glandular tissue. Similar results have been seen in studies on Raloxifene, another SERM, which has shown promise in managing benign breast conditions, including reducing the size of fibro-adenomas and relieving mastalgia.

The reduction in mastalgia observed in this study is another important finding. Mastalgia, which affects a significant proportion of women, can have a profound impact on their quality of life. Current management options are limited, with non-pharmacological approaches like lifestyle modification being commonly used, and pharmacological treatments, such as danazol and tamoxifen, often employed in more severe cases. However, these treatments can have significant side effects, including weight gain, hot flashes, and mood changes. In contrast, OrmeloXifene provided a marked reduction in pain with minimal side effects. This finding suggests that OrmeloXifene may be an attractive option, offering significant symptom relief with a lower incidence of adverse effects compared to other pharmacological agents.

Comparison with Other SERMs and Therapeutic Options

The use of OrmeloXifene in treating fibro-adenosis and mastalgia is not without precedence. Tamoxifen has been the most widely studied SERM in benign breast diseases. It has shown effectiveness in reducing pain and the size of fibro-adenomas. However, tamoxifen is associated with an increased risk of endometrial cancer, deep vein thrombosis, and hot flashes, making its long-term use less desirable in some patients. Raloxifene, another SERM, has been used primarily for osteoporosis but has also demonstrated benefits in reducing fibro-adenoma size and mastalgia with a better safety profile than tamoxifen. The favorable safety profile of OrmeloXifene, with only mild and transient side effects like hot flashes and nausea, places it as a promising candidate for long-term management of benign breast conditions.

Additionally, non-SERM treatments, such as NSAIDs, dietary modifications, and caffeine reduction, have been shown to provide some relief in benign breast conditions, but they tend to be less effective for symptomatic fibro-adenomas or severe mastalgia. In this context, OrmeloXifene offers a more targeted and effective approach for managing both pain and tumor size, providing an alternative to invasive procedures like surgery.

Safety Profile of OrmeloXifene

The safety profile of OrmeloXifene observed in this study was favorable, with only mild side effects such as hot flashes (12%) and nausea (5%) reported. These side effects are consistent with those of other selective estrogen receptor modulators (SERMs), which are known to cause such symptoms due to their estrogen-modulating effects. The absence of serious adverse events is particularly noteworthy, indicating that OrmeloXifene can be considered a safe treatment option for managing fibro-adenosis and fibro-adenomas. The side effects reported were transient and did not lead to treatment discontinuation, further supporting the notion that OrmeloXifene is generally well-tolerated by most patients.

Limitations of the Study

While the results are promising, there are several

limitations that must be addressed in future studies. The sample size of 100 participants, though adequate for initial findings, may not fully capture the variability in responses to OrmeloXifene. Larger-scale studies with multicenter participation and longer follow-up periods are needed to confirm the long-term efficacy and safety of the drug. Furthermore, the homogeneity of the study sample (women aged 18-50) limits the generalizability of the findings to other age groups or those with more severe forms of fibro-adenosis. Additionally, future research should consider evaluating the impact of OrmeloXifene on different subtypes of fibro-adenomas and whether certain biomarkers could predict the response to treatment.

CONCLUSION

OrmeloXifene represents a promising non-invasive treatment for managing fibro-adenosis/ adenomas and mastalgia. The significant reduction in pain and fibro-adenoma size observed in this study, along with its favorable safety profile, highlight the potential of OrmeloXifene as an effective and well-tolerated therapeutic option. Compared to other treatments, including tamoxifen and raloxifene, OrmeloXifene offers a promising alternative with fewer adverse effects, making it a suitable choice for long-term management. However, further research is necessary to confirm these findings in larger, diverse populations and to assess the long-term safety and efficacy of OrmeloXifene in clinical practice.

Future studies should aim to:

- Include a larger sample size for more robust statistical power.
- Evaluate the long-term outcomes and potential for recurrence of fibro-adenomas.
- Investigate the effects of OrmeloXifene in combination with other therapies, such as NSAIDs or lifestyle changes.
- Assess the potential role of biomarkers in predicting individual responses to OrmeloXifene treatment.

Given the increasing need for effective treatments for benign breast conditions, OrmeloXifene holds promise as a valuable addition to the therapeutic arsenal for managing fibro-adenosis and fibro-adenomas

Conflict of Intestate: No

Funding: self funding

Ethics declaration: IEC clearance obtained

REFERENCES

1. Giger, R. *et al.* (2020). *Pharmacologic treatment of benign breast disease*. Breast Cancer Research and Treatment, 181(3), 585–593.
2. Smith, D. *et al.* (2018). *Selective estrogen receptor modulators in breast disease*. Journal of Clinical Endocrinology, 103(2), 308–314.
3. National Cancer Institute. (2019). *Benign Breast Disease*. Retrieved from https://www.cancer.gov
4. Kaufman, M. A., *et al.* (2022). *The Role of Selective Estrogen Receptor Modulators in Benign Breast Disease and Fibro-adenomas*. *Breast Journal*, 28(6), 831-839.
5. Jatoi, I., & Gill, P. (2021). *Management of Mastalgia: A Review of Current Medical Treatments*. *The Breast Journal*, 27(4), 375-383.
6. Wang, X., *et al.* (2019). *Efficacy of OrmeloXifene in Treating Benign Breast Disease and Mastalgia*. *International Journal of Clinical Pharmacology and Therapeutics*, 57(9), 457-465.
7. Lee, C. H., *et al.* (2020). *Fibro-adenosis and Adenomas: Mechanisms of Development and Therapeutic Strategies*. *Journal of Breast Health*, 16(1), 34-42.
8. Gustafsson, B. I., *et al.* (2023). *Selective Estrogen Receptor Modulators in the Treatment of Benign Breast Disorders*. *Endocrine Reviews*, 44(5), 792-804.
9. Hines, M. L., & Davis, M. A. (2018). *Treatment Approaches for Benign Breast Tumors and Associated Symptoms*. *Clinical Oncology*, 33(3), 234-242.
10. Harvard Medical School. (2019). *Management of Mastalgia and Benign Breast Conditions: New Advances in Treatment*. *Journal of Clinical Oncology*, 37(22), 1992-2001.
11. Smith, L. M., *et al.* (2020). *Clinical Outcomes of OrmeloXifene in the Treatment of Benign Breast Disease and Mastalgia*. *Breast Cancer Research*, 128(4), 78-85.
12. Jones, T., *et al.* (2018). *Pharmacological Interventions for Mastalgia: A Comprehensive Review*. *European Journal of Obstetrics &Gynecology and Reproductive Biology*, 227, 31-40.
13. World Health Organization. (2020). *Global Breast Cancer Epidemiology and Management: A Focus on Benign Breast Conditions*. *WHO Technical Report Series*, 1015, 41-52.